These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 8383009)

  • 21. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
    Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity.
    Qiu J; Catapano CV; Fernandes DJ
    Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
    Bugg BY; Danks MK; Beck WT; Suttle DP
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7654-8. PubMed ID: 1652758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
    Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
    Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
    Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT
    Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
    Yu Q; Mirski SE; Sparks KE; Cole SP
    Biochemistry; 1997 May; 36(19):5868-77. PubMed ID: 9153428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucocorticoid receptor gene mutations in leukemic cells acquired in vitro and in vivo.
    Hillmann AG; Ramdas J; Multanen K; Norman MR; Harmon JM
    Cancer Res; 2000 Apr; 60(7):2056-62. PubMed ID: 10766198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
    Hammonds TR; Foster SR; Maxwell A
    J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
    Hong JH
    Hiroshima J Med Sci; 1989 Dec; 38(4):197-207. PubMed ID: 2561562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.
    Matsuo K; Kohno K; Takano H; Sato S; Kiue A; Kuwano M
    Cancer Res; 1990 Sep; 50(18):5819-24. PubMed ID: 2168282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Point mutations of the topoisomerase IIalpha gene in patients with small cell lung cancer treated with etoposide.
    Kubo A; Yoshikawa A; Hirashima T; Masuda N; Takada M; Takahara J; Fukuoka M; Nakagawa K
    Cancer Res; 1996 Mar; 56(6):1232-6. PubMed ID: 8640804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
    Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
    Biochemistry; 2003 Aug; 42(32):9749-54. PubMed ID: 12911317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.
    Withoff S; Smit EF; Meersma GJ; van den Berg A; Timmer-Bosscha H; Kok K; Postmus PE; Mulder NH; de Vries EG; Buys CH
    Lab Invest; 1994 Jul; 71(1):61-6. PubMed ID: 8041119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
    Bertrand R; Sarang M; Jenkin J; Kerrigan D; Pommier Y
    Cancer Res; 1991 Dec; 51(23 Pt 1):6280-5. PubMed ID: 1933888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a DNA topoisomerase IIalpha gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIalpha and the retinoic acid receptor alpha locus.
    McPherson JP; Brown GA; Goldenberg GJ
    Cancer Res; 1993 Dec; 53(24):5885-9. PubMed ID: 8261398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
    Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
    Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.